The Invisible Risk at Home: How Household Air Pollution Contributes to Lung Cancer

Indoor air pollution represents a chronic and under-recognized risk factor for lung cancer, silently contributing to a substantial portion of global cases, given that people spend up to 90% of their time indoors[1]. Unlike the visible haze of outdoor smog, indoor contaminants such as radon gas (naturally released from soil and granite), fine particulate matter (PM2.5; e.g. from burning candles or incense), cooking fumes, biomass smoke (from fireplaces or wood-burning stoves), and second-hand tobacco smoke accumulate gradually over years or decades, often without causing symptoms that would prompt concern[2]. This slow and insidious exposure allows carcinogens, including polycyclic aromatic hydrocarbons (PAHs), volatile organic compounds (VOCs), and radioactive radon decay products, to inflict persistent damage on lung tissue — a risk particularly relevant for never-smokers, who represent a growing proportion of lung cancer diagnoses worldwide.

Household air pollution (HAP) arises primarily from routine domestic activities, especially in poorly ventilated homes. The use of coal, wood, crop residues or animal dung for cooking and heating remains common in many regions and generates high concentrations of carcinogenic particles[3]. Radon, which seeps into buildings from soil and construction materials, is the second leading cause of lung cancer after smoking. Long-term exposure increases lung cancer risk by 6% to 16% for every 100 Bq per cubic metre increase in radon concentration, often without detection. Fine particles such as PM2.5 penetrate deep into the alveoli, where they trigger chronic inflammation, oxidative stress, and DNA damage. These processes are closely associated with adenocarcinoma, the lung cancer subtype most frequently observed in never-smokers and most strongly linked to air pollution[4].

Epidemiological data underscore the scale of this risk. Among non-smoking women in Asia exposed to biomass fuels or traditional cooking methods, lung cancer odds ratios have been reported as high as 8.13. Studies in China have also documented significantly elevated particulate levels in affected individuals, with lung cancer risk increasing by approximately 45% for every 10 micrograms per cubic meter rise in particulate exposure[5]. The World Health Organization estimates that indoor air pollution contributes to approximately 4 million deaths annually, including about 6% from lung cancer, disproportionately affecting rural and low-income populations[6]. Even in urban environments, exposure to cooking fumes, incense smoke, and inadequate ventilation produces similar biological effects. The presence of airborne carcinogen biomarkers in lung tissue and pleural fluid provides direct evidence of long-term accumulation and biological impact.

At the cellular level, chronic exposure to indoor pollutants creates conditions that support cancer development. Fine particles stimulate immune cells such as macrophages to release inflammatory cytokines, including IL-1β, which promote genetic mutations and create a tumor-supportive microenvironment[7]. These processes frequently affect alveolar type II cells, where oncogenic pathways such as EGFR signaling may become activated. Because these changes develop slowly and without acute symptoms, the link between indoor air pollution and cancer often remains unrecognized. Although particulate matter has been classified as a Group 1 carcinogen by the International Agency Research on Cancer, indoor sources have historically received less regulatory attention than outdoor air pollution.

Prolonged Exposure to Household Pollutants: Inflammation and Cellular Damage

Long-term exposure to household pollutants drives persistent inflammation and cellular injury in the lungs. Fine particles and toxic gases generated by biomass combustion, cooking oils, and indoor chemical emissions penetrate deeply into lung tissue, where they disrupt epithelial integrity and generate excessive reactive oxygen species. This oxidative stress depletes protective antioxidants such as glutathione and causes damage to cellular lipids, proteins, and DNA, creating conditions conducive to malignant transformation[8].

This oxidative damage activates inflammatory pathways, including NF-κB signaling, in both epithelial and immune cells. This results in sustained release of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α[9]. Over time, chronic inflammation impairs normal lung repair mechanisms, disrupts mitochondrial function, and promotes cellular senescence or apoptosis. Senescent cells further amplify inflammation and reinforce a cycle of ongoing tissue injury and immune dysregulation[10].

These biological changes are accompanied by epigenetic alterations, including telomere shortening and histone modification, which can silence tumor suppressor genes and promote genomic instability. Long-term exposure has also been linked to early fibrotic changes and precancerous lesions, particularly among populations exposed to biomass smoke for decades. Because these processes progress silently, damage often becomes apparent only after irreversible changes have occurred.

Encouragingly, interventions such as improved ventilation, clean fuels, and indoor air quality monitoring can significantly reduce exposure and interrupt these pathogenic mechanisms.

Why Domestic Environments Matter in Lung Cancer Prevention?

Domestic environments must play a central role in cancer prevention strategies. While tobacco control remains essential, indoor environmental exposures represent a significant and often overlooked source of risk.

Never-smokers now account for approximately 15% to 20% of global lung cancer cases, many linked to environmental exposures rather than tobacco use. Household air pollution contributes to millions of deaths annually, including a substantial number from lung cancer, particularly in low- and middle-income regions[11].

The risk is especially pronounced among populations exposed to biomass cooking fuels, poor ventilation, and radon infiltration. Biomarkers detected in lung tissue confirm that carcinogenic compounds originating within the home accumulate over time and reinforce the need to address domestic air quality as a core component of prevention efforts[12].

Reducing household air pollution represents one of the most actionable opportunities to lower lung cancer risk globally. Improving ventilation, transitioning to clean energy sources, testing for radon, and increasing awareness can significantly reduce long-term exposure. Recognizing the home as a critical environment for prevention is essential to addressing the full spectrum of lung cancer risk.

References:

1. Slater, K. D. (2025). Characterizing Associations Between Household Energy-Related Exposures to Air Pollution and Biological Indicators of Respiratory Health (Doctoral dissertation, Colorado State University).

2. Valavanidis, A. (2023). Indoor air pollution causes around 4 million premature deaths worldwide per year.

3. Ezzati, M., & Kammen, D. M. (2002). Household energy, indoor air pollution, and health in developing countries: knowledge base for effective interventions. Annual review of energy and the environment, 27 (1), 233-270.

4. Valavanidis, A. (2019). Oxidative stress and pulmonary carcinogenesis through mechanisms of reactive oxygen species. How respirable particulate matter, fibrous dusts, and ozone cause pulmonary inflammation and initiate lung carcinogenesis. In Oxidative Stress in Lung Diseases: Volume 1 (pp. 247-265). Singapore: Springer Singapore. doi: https://doi.org/10.1007/978-981-13-8413-4_13

5. Wang, M., Kim, R. Y., Kohonen-Corish, M. R., Chen, H., Donovan, C., & Oliver, B. G. (2025). Particulate matter air pollution as a cause of lung cancer: epidemiological and experimental evidence. British journal of cancer, 132 (11), 986. doi: https://doi.org/10.1038/s41416-025-02999-2

6. Busolo, W. S., & Njabira, V. I. (2022). Air Quality. In The Palgrave Handbook of Urban Development Planning in Africa (pp. 327-372). Cham: Springer International Publishing. doi: https://doi.org/10.1007/978-3-031-06089-2_12

7. Chang, C. Y., Armstrong, D., Corry, D. B., & Kheradmand, F. (2023). Alveolar macrophages in lung cancer: opportunities and challenges. Frontiers in Immunology, 14, 1268939. doi: https://doi.org/10.3389/fimmu.2023.1268939

8. Jomova, K., Alomar, S. Y., Valko, R., Fresser, L., Nepovimova, E., Kuca, K., & Valko, M. (2025). Interplay of oxidative stress and antioxidant mechanisms in cancer development and progression. Archives of Toxicology, 1-47. doi: https://doi.org/10.1007/s00204-025-04146-5

9. Gandhi, D., Bhandari, S., Maity, S., Mahapatra, S. K., & Rajasekaran, S. (2025). Activation of ERK/NF-kB Pathways Contributes to the Inflammatory Response in Epithelial Cells and Macrophages Following Manganese Exposure. Biological Trace Element Research, 203 (1), 127-138. doi: https://doi.org/10.1007/s12011-024-04154-z

10. Liu, S., Xi, Q., Li, X., & Liu, H. (2025). Mitochondrial dysfunction and alveolar type II epithelial cell senescence: The destroyer and rescuer of idiopathic pulmonary fibrosis. Frontiers in Cell and Developmental Biology, 13, 1535601. doi: https://doi.org/10.3389/fcell.2025.1535601

11. Lai, P. S., Lam, N. L., Gallery, B., Lee, A. G., Adair-Rohani, H., Alexander, D., … & Ozoh, O. B. (2024). Household air pollution interventions to improve health in low-and middle-income countries: an official American thoracic society research statement. American Journal of Respiratory and Critical Care Medicine, 209 (8), 909-927. doi: https://doi.org/10.1164/rccm.202402-0398ST

12. Hudson-Hanley, B. A. (2022). Polycyclic Aromatic Hydrocarbons (PAH) Exposure Trends, and Evidence of Adverse Health Effects in Infants and Children from Prenatal/Early-Life PAH Exposure.

Jacek Antas

Chief Executive Officer


Jacek Antas is a shareholder of the Company, has spent more than 25 years in the financial services industry holding various positions in sales and consulting.

Mr. Antas obtained a master’s degree from the Warsaw School of Economics and has served as a board member of various
companies throughout his career.

This will close in 0 seconds

James B. Murphy

Chief Financial Officer


Mr. Murphy is a certified public accountant with over thirty years of experience in finance and operations management. He is currently a consultant with Danforth Advisors LLC (“Danforth”), a leading provider of outsourced strategic and operational specialists across functions in the life sciences industry. While at Danforth, Mr. Murphy has served over fifteen private and publicly held life sciences companies as CFO and CFO Advisor, helping them secure over USD 0.5 billion in financing and successfully execute pivotal asset transactions. Mr. Murphy functions as a consultant to Helix pursuant to a consulting agreement between the Company and Danforth.

This will close in 0 seconds

Thomas Mehrling

Medical Adviser


Thomas Mehrling (PhD in Pharmacology and MD) has over 20 years’ experience in multinational Pharma companies developing novel oncology compounds from preclinical research through to registration. Prior to entering the industry, he spent 13 years as an MD at the University Hospital in Frankfurt, working on preclinical and translational projects. He served as Director of European Oncology at Mundipharma International (2003–2013), building the company’s first European oncology business from the ground up out of Cambridge, UK, and completing the clinical development, registration and launch of two major products in Europe, DepoCyte® and Levact® (Ribomustin® and Treanda®). In 2013, he led the establishment of the Mundipharma Group’s start-up, Mundipharma EDO, developing anti-cancer therapeutics for solid tumours out of Basel, Switzerland.

This will close in 0 seconds

Kim Gaspar

Director Quality Assurance


Kim is the Director of Quality Assurance at Helix BioPharma Corp. An experienced quality assurance professional with expertise in Canadian, US, and EU regulations, she has been involved in all aspects of Phase I/II biopharmaceutical product development over the years, including regulatory submissions, QC laboratory compliance, tech transfer and third-party oversight of CMC activities, clinical QA, and bioanalytical data analysis. Kim joined Helix in 2000, transitioning into QA in 2003. She holds a B.Sc in Biochemistry and a Ph.D in Veterinary Physiological Sciences, both from the University of Saskatchewan.

This will close in 0 seconds

Brenda Lee

Director Clinical Operations


Brenda is the Clinical Operations Director at Helix Biopharma Corp. A clinical research operations professional with 25 years of experience managing clinical trials, ranging from early Phase I to late Phase IIIb/IV studies, she brings experience in clinical study protocol writing and development, trial start-up and vendor management, and a proven track record in planning and managing clinical trials to quality standards, timelines and budget. Brenda joined Helix Biopharma Corp. in 2018, working to advance the clinical program of L-DOS47. She holds B.Sc and M.Sc. degrees from the University of Toronto, specializing in Nutritional Sciences and Human Biology.

This will close in 0 seconds

Jerzy Leszczynski

Director


Jerzy Leszczynski is a shareholder of the Company, has spent more than 35 years developing businesses and has served in the capacity of board member of various real estate development companies. Mr. Leszczynski obtained his Master of Science in Chemistry from the Warsaw Institute of Technology.

This will close in 0 seconds

Janusz Grabski

Director, Chair of Audit Committee


Janusz (John) Grabski is a lawyer specialized in corporate and real estate law with over twenty years of experience.

This will close in 0 seconds

Malgorzata Laube

Director


Malgorzata Laube has over 19 years of experience in nuclear medicine. In her last role with Alberta Health Services, she was the Department Supervisor, Nuclear Medicine at Royal Alexandra Hospital. Ms. Laube obtained a MSc degree in Environmental Engineering from the Warsaw University of Technology and is based in Edmonton, Alberta, Canada.

This will close in 0 seconds

Jacek Antas

Chairman of the Board


Jacek Antas is a shareholder of the Company, has spent more than 25 years in the financial services industry holding various positions in sales and consulting.

Mr. Antas obtained a master’s degree from the Warsaw School of Economics and has served as a board member of various
companies throughout his career.

This will close in 0 seconds

Jonathan Davis

Advisor, ADC Discovery


Jonathan Davis received his Ph.D. from University of California, San Francisco, where he studied protein structure and function using NMR. After a post-doc at Harvard Medical School exploring RNA selection and structure in the labs of Jack Szostak and Gerhard Wagner, he went to work at EMD Serono, where his work involved improving antibody-based therapeutics, inventing a platform technology for generating heterodimeric Fcs as a basis for multifunctional molecules, and developing a novel scaffold based on an artificially-designed protein from David Baker’s lab. In 2008 he took a job at Bristol-Myers Squibb in Waltham/Cambridge MA, working on antibody discovery and platform development in a wide range of therapeutic areas, with a particular focus on multispecific therapeutics. He moved to Madison, WI in 2019 to take on the role of VP of Innovation and Strategy at Invenra, a biotech focused on bispecific antibodies, and where he is currently head of the Scientific Advisory Board. In early 2024 he left the corporate world to found Creative Antibodies, a consulting firm that helps guide companies to successful antibody discovery and development projects, from mAbs to multispecifics, ADCs, and other formats. Outside of science, Jonathan is a conservatory trained cellist, plays numerous other instruments, and founded the UCSF Orchestra (now Symphony Parnassus) in San Francisco, where he was Music Director for six years.

This will close in 0 seconds

Davide Guggi

Advisor, CMC


Davide graduated as a pharmacist and received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. He has over 20 years of experience in the pharmaceutical industry, principally in the field of oncology. At the beginning of his career, Davide led oncology business units and commercial departments at Mundipharma and Gilead across Austria and Eastern Europe. Since over 10 years he has been working as a CMC expert, covering operational and regulatory CMC functions on behalf of over 20 different small- and medium-sized biotech companies across the world. He has served as CMC Director and CSO/CTO for several years, developing both small molecules and biologics (mABs, Fab, ADCs and Radio-immuno-conjugates) from early discovery to NDA/BLA in the US, EU and Canada, with a focus on First-in-Human and Phase I/II studies in oncology indications.

This will close in 0 seconds

This will close in 0 seconds

Tumor Defense Breaker™, L-DOS47


L‑DOS47 is a first‑in‑class, clinical-stage antibody‑enzyme conjugate designed to deliver a game-changing assist to anti-cancer immunity and today’s leading cancer immunotherapies for the treatment of prevalent, hard-to-treat solid tumors. The compound precisely targets CEACAM6, a cell-surface protein overexpressed in non‑small cell lung cancer (NSCLC) and other aggressive tumors, where it delivers an enzymatic payload that raises the extracellular pH of the acidic tumor microenvironment (TME). By neutralizing tumor acidity, L-DOS47 restores immune cell infiltration and activity, helps turn immunologically “cold” tumors “hot”, and enhances the therapeutic reach of immune checkpoint inhibitors. With patented composition-of-matter coverage through 2036 and demonstrated synergy with PD-1 inhibitor, pembrolizumab, L-DOS47 is poised to significantly increase the efficacy of immune checkpoint blockade and unlock broader and more durable responses in NSCLC and other aggressive solid tumors.

This will close in 0 seconds

LEUMUNA™


LEUMUNA™ is an oral immune checkpoint modulator designed to activate the donor immune system to recognize and fight relapsing leukemia in patients who have undergone allogeneic stem cell transplantation (allo-SCT). Although a life-saving procedure, up to 30% of patients who undergo allo-SCT see their cancer return, facing a median survival of just four months. LEUMUNA aims to offer these patients a new lease on life, by activating an immune cascade and inciting graft-versus-leukemia (GvL) effect, potentially offering long-term remission. Backed by strong preclinical data and a promising safety record from trials with its precursor compound, ulodesine, LEUMUNA offers a patient‑friendly, oral approach to a difficult-to-treat condition, with patent protection through 2041 and an Orphan Drug Designation granted by the US FDA.

This will close in 0 seconds

GEMCEDA™


GEMCEDA is a first-in-class oral prodrug of gemcitabine that opens up the possibility for convenient at-home administration, metronomic dosing and seamless integration into combination regimens with immune checkpoint inhibitors. To date, gemcitabine is only administered intravenously because oral forms have shown poor bioavailability of about 10%. GEMCEDA was developed as a prodrug to enable new uses of gemcitabine by combining it with cedazuridine, an enzyme inhibitor that helps boost its bioavailability to 90%. This remarkable innovation allows for greater flexibility in dosing schedules, fewer clinic visits, and a better quality of life, while achieving bioavailability on par with intravenous gemcitabine. Supported by a well‑established safety profile, scalable manufacturing, and patent coverage to 2043, GEMCEDA reimagines how chemotherapy can fit into patients’ lives.

This will close in 0 seconds